Medgenics Inc

Type: Company
Name: Medgenics Inc
First reported Apr 15 2014 - Updated Apr 16 2014 - 2 reports

Medgenics Awarded $2.2 Million Grant From the Israeli Office of the Chief Scientist

Medgenics, Inc. (NYSE MKT:MDGN) (LSE:MEDU) (LSE:MEDG), the developer of BioPump(TM) a novel technology for the sustained production and delivery of therapeutic proteins in patients using ex-vivo gene therapy and their own tissue for the treatment of rare ... [Published Citybizlist - Apr 16 2014]
First reported Apr 10 2014 - Updated Apr 10 2014 - 1 reports

Peregrine Reports Data on Bavituximab; Keryx Reports Zerenex Phase 2 Results

Below is a look at some of the headlines for companies that made news in the healthcare sector on April 9, 2014.Peregrine Pharmaceuticals (NASDAQ: PPHM) announced data from studies validating the immune-stimulatory mechanism of action of bavituximab and ... [Published BioMedReports - Apr 10 2014]
Entities: Bavituximab, Tumor, Antibody
First reported Nov 15 2013 - Updated Nov 15 2013 - 1 reports

Directors Dealings

Medgenics, Inc. (AIM: MEDU, MEDG and NYSE MKT: MDGN), the developer of BiopumpTM, a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces that, on 11 November 2013 it was informed ... [Published TrustNet - Nov 15 2013]
First reported Nov 07 2013 - Updated Nov 07 2013 - 1 reports

Medgenics net losses rise

Medgenics Inc ShsUSD0.0001Regs (MEDG) Medgenics Inc ShsUSD0.0001(DI) (MEDU) Medgenics posts a third quarter net loss of $6.14m or $0.33 per share, compared with a net loss of $3.03m or $0.25 per share a year ago. The company is the developer of a novel ... [Published TrustNet - Nov 07 2013]
First reported Oct 23 2013 - Updated Oct 23 2013 - 1 reports

Medgenics to present poster at ESGCT Congress

Medgenics To Present Poster at European Society of Gene and Cell Therapy Congress to Highlight Results from Second-Generation Viral Vector Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the "Company"), the developer of a novel technology for the ... [Published TrustNet - Oct 23 2013]

Quotes

"We are delighted and honored to once again have been selected to receive this non-dilutive funding from the Israeli OCS and appreciate the continued support. These grants have been instrumental in furthering the development of our BioPump technology and support us in advancing our clinical trials in the U S and Israel" stated Garry A Neil, Global Head of R&D for Medgenics
...suppressor cells and providing increased tumor-specific immunity," said Jeff T Hutchins, Ph D , vice president of preclinical research at Peregrine. "These data also show that when combined with downstream immune checkpoint inhibitors such as anti-CTLA-4 and anti-PD-1, PS targeting mediates an improved protective tumor-specific immunity following tumor rechallenge. While these new downstream checkpoint inhibitors have been shown to strengthen the tumor-killing activity of T-cells and thus extend survival in some patients, there remains a need to increase the number of responders that mount anti-tumor T-cell responses in order to maximize the effects of these downstream checkpoint inhibitors. We believe a PS-targeting antibody, such as bavituximab, plays a key role in reducing tumor suppression and driving a more inclusive immune-mediated response. Insights from these data will influence our future clinical development plans including the soon to be opened investigator-sponsored trial assessing the potential of bavituximab and an anti-CTLA-4 antibody in patients with advanced melanoma."
...m. to 12:00 p.m. The following Medgenics' poster will be presented during Poster Session B on Sunday, October 27: $ "Second generation EPODURE Biopump? markedly extends duration of EPO delivery in mice, could prolong therapeutic effect in patients" by Miari, et al. Poster Number P146...

More Content

All (9) | News (7) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (2)
sort by: Date | Relevance
Medgenics Awarded $2.2 Million Grant From the I... [Published Citybizlist - Apr 16 2014]
Medgenics unit gets $2.2m grant [Published Telegraph - Apr 15 2014]
Peregrine Reports Data on Bavituximab; Keryx Re... [Published BioMedReports - Apr 10 2014]
Faruqi & Faruqi, LLP Launches An Investigation ... [Published Financial Services - Mar 14 2014]
Medgenics, Inc. to Present at the 26th Annual R... [Published GlobeNewswire: Acquisitions News - Mar 05 2014]
Directors Dealings [Published TrustNet - Nov 15 2013]
Medgenics net losses rise [Published TrustNet - Nov 07 2013]
Medgenics to present poster at ESGCT Congress [Published TrustNet - Oct 23 2013]
Appointment of Nominated Adviser and Joint Broker [Published TrustNet - Oct 01 2013]
1
In Focus
Content Volume
Document Volume
Network
Network

Press Releases

sort by: Date | Relevance
Faruqi & Faruqi, LLP Launches An Investigation ... [Published Financial Services - Mar 14 2014]
Medgenics, Inc. to Present at the 26th Annual R... [Published GlobeNewswire: Acquisitions News - Mar 05 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.